Maxim Group Reiterates Buy Rating on Zevra Therapeutics

Maxim Group has reiterated its buy rating for Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), maintaining a price target of $35. This update from analyst Jason McCarthy was announced on June 10, 2026, as the stock traded at $12.96.

Zevra Therapeutics Stock Snapshot

Shares of Zevra Therapeutics are trading around $12.96, with a market capitalization of approximately $747.8 million. The company's P/E ratio is 6.29, while the forward P/E is 10.59. The stock's beta is 0.894, indicating it is less volatile than the market. Over the past 52 weeks, the stock has ranged from a low of $7.16 to a high of $14.27. Zevra's 50-day moving average is $10.71, and its 200-day moving average stands at $9.52.

Recent Earnings

Zevra reported revenue of $122.3 million, reflecting a growth rate of 77.5%. The company's earnings per share (EPS) is $2.01, with a net margin of 101.6% and return on equity (ROE) of 100.7%. Investors are looking forward to the next earnings announcement scheduled for May 6, 2026.

Insider Buying and Selling at Zevra Therapeutics, Inc.

Insider activity at Zevra includes Timothy Sangiovanni, SVP of Finance & Corp Controller, purchasing a total of 60,000 shares on May 28, 2026. Additionally, Rahsaan Thompson, Chief Legal & Compliance, sold 1,794 shares at $11.30 on May 11, 2026, under a planned transaction.

Analysts Set New Price Targets

On June 10, 2026, Maxim Group maintained its buy rating for Zevra Therapeutics with a $35 price target. On the same day, Guggenheim also maintained a buy rating with a $29 target. Canaccord Genuity reiterated their buy rating with a $29 target on June 11, 2026. The consensus among analysts is a strong buy, with an average target price of $27.89 from nine analysts.

About Zevra Therapeutics

Zevra Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing treatments for rare diseases using its Ligand Activated Technology platform. The company's lead products include KP1077 for idiopathic hypersomnia and narcolepsy, Celiprolol for vascular Ehlers Danlos syndrome, and AZSTARYS for ADHD. Zevra also develops OLPRUVA for urea cycle disorders and MIPLYFFA for Niemann-Pick disease type C. Led by CEO Neil F. McFarlane, Zevra employs 61 individuals.

Bottom Line

Maxim Group's reiteration of a buy rating with a $35 target reflects continued confidence in Zevra Therapeutics' potential. Investors monitor these updates for insights into the company's valuation and market perception. However, it's important to remember that analyst ratings are based on past performance and projections, which may not reflect current conditions.